Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

Proceedings of the National Academy of Sciences of the United States of America - 12 Apr 2005

Tate Sarah K, Depondt Chantal, Sisodiya Sanjay M, Cavalleri Gianpiero L, Schorge Stephanie, Soranzo Nicole, Thom Maria, Sen Arjune, Shorvon Simon D, Sander Josemir W, Wood Nicholas W, Goldstein David B

Abstract excerpt

Phenytoin and carbamazepine are effective and inexpensive anti-epileptic drugs (AEDs). As with many AEDs, a broad range of doses is used, with the final "maintenance" dose normally determined by trial and error. Although many genes could influence response to these medicines, there are obvious candidates. Both drugs target the alpha-subunit of the sodium channel, encoded by the SCN family of genes. Phenytoin is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamazepine

Share to Cytochrome P-450 CYP2C9

Share to Epilepsy

Share to NAV1.1 Voltage-Gated Sodium Channel

Share to Phenytoin

Share to Sodium Channels

Source

Open in PubMed Open full text

Identifiers

PMID: 15805193
DOI: 10.1073/pnas.0407346102
PMCID: PMC556232

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.PMID 15805193Read ↗

A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance doseSemantic proximity Read ↗

Genetic predictors for epilepsy development, treatment response and dosingSemantic proximity Read ↗

Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing.Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.Semantic proximity Read ↗

Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.Semantic proximity Read ↗

Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.Semantic proximity Read ↗

The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsySemantic proximity Read ↗

Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.Semantic proximity Read ↗

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.Semantic proximity Read ↗

Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy.Semantic proximity Read ↗

Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug TherapySemantic proximity Read ↗

A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.